|
Reduced ribosomal RNA expression and increased ribosomal DNA promoter methylation in CD34+ cells of patients with myelodysplastic syndromes
|
Oct 2012
|
Blood
|
myelodysplastic syndromes (MDS)
|
|
How I Treat Paroxysmal nocturnal hemoglobinuria
|
Jan 2021
|
Blood
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
|
Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes
|
Apr 2015
|
Blood
|
myelodysplastic syndromes (MDS)
|
|
GATA2 deficiency-associated bone marrow disorder differs from idiopathic aplastic anemia
|
Oct 2014
|
Blood
|
aplastic anemia
|
|
Ipilimumab plus decitabine for patients with MDS or AML in posttransplant or transplant-naïve settings
|
Apr 2023
|
Blood
|
myelodysplastic syndromes (MDS)
|
|
Cyclophosphamide in severe aplastic anemia?
|
Oct 2014
|
Blood
|
aplastic anemia
|
|
Camitta BM, Thomas ED, Nathan DG, et al. Severe aplastic anemia: a prospective study of the effect of early marrow transplantation on acute mortality. Blood. 1976;48(1):63-70
|
Nov 2016
|
Blood
|
aplastic anemia
|
|
The myelodysplastic syndrome as a prototypical epigenetic disease.
|
May 2013
|
Blood
|
myelodysplastic syndromes (MDS)
|
|
Assessing complement blockade in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab
|
Dec 2014
|
Blood
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
|
Revised International Prognostic Scoring System (IPSS-R) for myelodysplastic syndromes
|
Jun 2012
|
Blood
|
myelodysplastic syndromes (MDS)
|
